Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label safety and tolerability of dabigatran oral liquid for 3 days after standard anticoagulant therapy in children with VTE
2009-013618-29Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dabigatran in venous thromboembolism (VTE) (2 cohorts), sponsored by Boehringer Ingelheim. Primary endpoint: Incidence of all bleeding events. Started Apr 2010; status: completed.
02
Drugs
dabigatran
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2009-013618-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013618-29.